

## Efficacy of two doses of COVID-19 vaccine against severe COVID-19 in those with risk conditions and residual risk to the clinically extremely vulnerable: the REACT-SCOT case-control study

Paul M McKeigue <sup>1 6 \*</sup>, David A McAllister <sup>2 6</sup>, Chris Robertson <sup>3 6</sup>, Sharon Hutchinson <sup>4 6</sup>, Stuart McGurnaghan <sup>5</sup>, Diane Stockton <sup>6</sup>, Helen M Colhoun <sup>5 6</sup>, for the PHS COVID-19 Epidemiology and Research Cell <sup>6</sup>

**1** Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Teviot Place, Edinburgh EH8 9AG, Scotland.

**2** Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens, Glasgow G12 8RZ.

**3** Department of Mathematics and Statistics, University of Strathclyde, 16 Richmond Street, Glasgow G1 1XQ.

**4** School of Health and Life Sciences, Glasgow Caledonian University. SH - Professor of Epidemiology and Population Health

**5** Institute of Genetics and Cancer, College of Medicine and Veterinary Medicine, University of Edinburgh, Western General Hospital Campus, Crewe Road, Edinburgh EH4 2XUC, Scotland.

**6** Public Health Scotland, Meridian Court, 5 Cadogan Street, Glasgow G2 6QE

\* Corresponding author: [paul.mckeigue@ed.ac.uk](mailto:paul.mckeigue@ed.ac.uk)

## Abstract

**Objectives** - To determine whether COVID-19 efficacy varies with clinical risk category and to investigate risk factors for severe COVID-19 in those who have received two doses of vaccine.

**Design** - Matched case-control study (REACT-SCOT).

**Setting** - Population of Scotland from 1 December 2020 to 8 September 2021.

**Main outcome measure** - Severe COVID-19, defined as cases with entry to critical care or fatal outcome.

**Results** - Efficacy against severe COVID-19 of two doses of vaccine was 94% (95 percent CI 93% to 96%) in those without designated risk conditions, 89% (95 percent CI 86% to 91%) in those with moderate risk conditions, but only 73% (95 percent CI 64% to 79%) in those designated as clinically extremely vulnerable (CEV) and eligible for shielding.

Of the 641 cases of severe COVID-19 in double-vaccinated individuals, 47% had moderate risk conditions and 38% were CEV. In the double-vaccinated CEV group, the rate ratio for severe disease (with no risk condition as reference category) was highest in solid organ transplants at 101 (95% CI 47 to 214) but even in this subgroup the absolute risk of severe COVID-19 was low (35 cases in 23678 person-months of follow-up).

**Conclusions** - Two doses of vaccine protect against severe COVID-19 in CEV individuals but the residual risk in double-vaccinated individuals remains far higher in those who are CEV than in those who are not. These results lay a basis for determining eligibility for additional measures including passive immunization to protect those at highest risk.

## Introduction

The REACT-SCOT matched case-control study was established by Public Health Scotland at the beginning of the epidemic to investigate risk factors for severe COVID-19 [1]. Using this framework, we have reported on the relation of severe COVID-19 to risk conditions including those designated as clinically extremely vulnerable (CEV) and therefore eligible for the shielding programme in Scotland [1–3]. We have previously reported a comparison of the efficacy of vaccination against severe COVID-19 between CEV people and those with moderate risk conditions or no risk conditions, based on data up to 16 March 2021 [4]. At this time few individuals had received a second dose of vaccine, but since then most CEV individuals have received two doses. This report updates and extends the earlier analyses, with the following objectives:

1. To determine whether vaccine efficacy varies with risk category and CEV status now that more data, including exposure to two doses of vaccine, are available and now that the Delta variant is the dominant variant in Scotland.
2. To investigate risk factors for severe or hospitalised COVID-19 in those who have received two doses of vaccine.

## Methods

We used the REACT-SCOT study to take advantage of data linkages already established. The design has been described in detail previously [1]. In brief, for every incident case of COVID-19 in the population ten controls matched for one-year age, sex and primary care practice and alive on the day of presentation of the case that they were matched to were selected using the Community Health Index database. COVID-19 cases are those with a positive nucleic acid test, or a hospital admission or death with COVID-19 ICD-10 codes. The REACT-SCOT case-control dataset is refreshed regularly and is linked to the vaccination database and to the regularly updated dataset of all individuals deemed eligible for the shielding programme. Though the data extract included cases presenting up to 22 September 2021, the analyses reported here are restricted to cases and controls presenting from 1 December 2020 to 8 September 2021, ensuring follow-up for at least 14 days after presentation date to allow cases to be classified as severe or hospitalised.

### Classification of risk categories

As previously [1], to minimise ascertainment bias we pre-specified the primary outcome measure as severe COVID-19, defined as diagnosed cases with entry to critical care within 28 days of presentation or fatal outcome (any death within 28 days of a positive test or any death for which COVID-19 was coded as underlying cause). Cases and controls were classified into three broad risk categories: no risk condition; at least one of the moderate risk conditions designated by public health agencies [1]; or CEV (eligible for shielding) [3]. For further analyses, the CEV category was subdivided as described previously into six categories: solid organ transplant, specific cancers, severe respiratory conditions, other rare conditions, on immunosuppressants, and additional conditions [3]. This corresponds to the list used by Public Health Scotland [5], after combining the small numbers in the group

“pregnant with heart disease with the”other conditions” category. For additional analyses 62  
the category “specific cancers” was split to allocate cancers of blood-forming organs 63  
(ICD-10 codes C81-C88, C90-C96) to a separate category. 64

## Statistical analysis 65

The matched design controls for age, sex, general practice and calendar time to single day. 66  
Covariates included in the models were those that have been previously identified as strong 67  
predictors of severe disease in this population: care home residence, number of adults in 68  
household, number of non-cardiovascular drug classes dispensed and recent hospital stay 69  
[1–3]. For care home residents the number of of adults in the household was coded as 1 to 70  
ensure that these two variables are not confounded. The number of non-cardiovascular drug 71  
classes was calculated as the number of distinct BNF subparagraph codes for which a 72  
prescription was dispensed between 15 and 255 days before presentation date. The number 73  
of hospital diagnoses was calculated as the number of distinct ICD-10 chapters represented 74  
at least once in hospital discharge records between 25 days and 5 years before presentation 75  
date. Recent hospital stay was defined as any in-patient stay from 5 to 14 days before 76  
presentation date. 77

Vaccination status was coded as the number of doses administered at least 14 days 78  
before presentation date. Vaccine doses administered less than 14 days before presentation 79  
date were ignored. The effect of vaccination in each of the clinical vulnerability categories 80  
was estimated in a conditional logistic regression model specifying effects  $\beta_{R2}, \dots, \beta_{RJ}$  for 81  
the log rate ratio associated with risk categories 2 to  $J$  ( $\beta_{R1} = 0$  for the reference category 82  
 $J = 1$ ), and nested effects  $\beta_{V1}, \dots, \beta_{VJ}$  for the log rate ratio associated with vaccination in 83  
each of the  $J$  risk categories. With this incidence density sampling design, the conditional 84  
odds ratio is the rate ratio. The efficacy of vaccination is 1 minus the rate ratio [6]. The 85  
unconditional odds ratios calculated from frequency tables of the vaccination status of cases 86  
and controls in each risk group cannot be used to estimate rate ratios [7,8]. 87

## Cohort analysis of the shielding list 88

The case-control study estimates only rate ratios. To investigate how the absolute rates of 89  
severe disease in those listed as clinically extremely vulnerable have changed with the 90  
vaccination programme rollout, we also undertook a cohort analysis of all individuals who 91  
had ever been on the shielding list. A Poisson regression model was fitted to the cohort 92  
formatted with one observation per 28-day person-time interval, and individuals censored at 93  
first diagnosis of COVID-19. Event status was defined as severe COVID-19 presenting 94  
within the person-time interval, and the covariates were sex, baseline age, and shielding 95  
eligibility group. The baseline hazard rate was modelled as a natural spline function of 96  
calendar time with 6 degrees of freedom. To allow comparison with how the rates of all 97  
diagnosed cases varied with calendar time, a similar model was fitted with event status 98  
defined as any diagnosed case. 99

## Results

100

### Relation of vaccine efficacy to risk conditions

101

As shown in Table 1 from 1 December 2020 to 8 September 2021 there were 5644 cases of severe COVID-19 in the total population of Scotland of whom 28% had no designated risk condition, 51% had a moderate risk condition and 21% were CEV. The distributions in cases and controls of other risk factors included as covariates in the models are shown for completeness. Overall 80% of severe cases arising in this period were not yet vaccinated. Table S1 shows the same tabulation with case definition broadened to include all 21671 hospitalised cases and their matched controls.

108

Table 2 shows rate ratios associated with 1 and 2 vaccine doses (with 0 doses as reference category) in each of the three broad risk categories from the conditional logistic regression model. The model included risk categories (no risk conditions as reference category), care home residence, number of adults in household, number of drug classes and recent hospital stay as covariates. The rate ratio associated with two doses of vaccine was 0.06 (95% CI 0.04 to 0.07) in those without risk conditions, 0.11 (95% CI 0.09 to 0.14) in those with moderate risk conditions, and 0.27 (95% CI 0.21 to 0.36) in the CEV group. On the scale of efficacy, these estimates are equivalent to 94% (95 percent CI 93% to 96%) in those without risk conditions, 89% (95 percent CI 86% to 91%) in those with moderate risk conditions, and 73% (95 percent CI 64% to 79%) in the CEV group. Table S2 shows the same model with case definition broadened to include all hospitalised cases and their matched controls: the efficacy of 2 doses against hospitalisation also was lower at 68% (95 percent CI 63% to 71%) in the CEV than in the other two risk categories. The difference in vaccine efficacy against hospitalisation between the CEV group and the other two risk categories was not explained by differences in time since second dose.

123

Table 3 shows rate ratios associated with vaccination by risk group with the CEV group subdivided into six categories. Rate ratios were higher (and thus efficacy was lower) in all CEV subgroups than in those without risk conditions or with moderate risk conditions, but the confidence intervals were too wide for comparisons of efficacy between CEV subgroups. Within the “Specific cancers” group, efficacy of two doses did not differ between those with blood cancers and those with other types of cancer but the confidence intervals were wide. Table S3 shows rate ratios for the first and second dose with the case definition broadened to include all hospitalised cases and their matched controls. In this table the highest rate ratio (lowest efficacy) is in solid organ transplant recipients but again the confidence intervals are too wide for comparisons of efficacy between CEV subgroups.

133

We examined whether there was any difference in efficacy by class of vaccine and whether any such differences varied by risk category. Table 4 shows rate ratios associated with 1 and 2 doses of each class of vaccine (with 0 doses as reference category) in each of the three broad risk categories. Table S4 shows the same model with case definition broadened to include all hospitalised cases and their matched controls. Although the confidence intervals for the rate ratios associated with 1 or 2 doses of each vaccine product in the CEV group are wide, it is clear that for both classes of vaccine product the efficacy of 2 doses is lower in the CEV group than in those with moderate risk conditions or no risk conditions. Efficacy of two doses against severe COVID-19 in the CEV group did not differ between the AstraZeneca vaccine [72% (95 percent CI 63% to 79%)] and the mRNA vaccines [73% (95 percent CI 59% to 83%)] Further comparison of efficacy of the two

144

vaccine types in CEV individuals has been reported elsewhere [9]. 145

## Risk factors for severe COVID-19 in the double-vaccinated 146

Table 5 shows risk factors for severe COVID-19 in cases and controls who had received 2 147  
doses of vaccine at least 14 days before presentation date. Table S5 shows the same analysis 148  
with case definition broadened to include hospitalized cases and matched controls who had 149  
received 2 doses of vaccine. Only 15% of double-vaccinated severe cases had no designated 150  
risk condition: 47% had at least one moderate risk condition and 38% were CEV. Of the 151  
variables that we have previously reported as risk factors for severe COVID-19 in the general 152  
population, care home residence and socioeconomic deprivation were not associated with 153  
severe disease in the double-vaccinated. In this group the risk factors for severe disease were 154  
designated risk conditions, other indicators of co-morbidity including numbers of hospital 155  
diagnoses and drug classes prescribed and transmission-related factors including number of 156  
adults in household and recent hospital stay. A risk score for hospitalised or fatal COVID-19 157  
in the double-vaccinated calculated from the multivariable conditional logistic regression 158  
model in Table S5 was able to distinguish severe cases from noncases with a C-statistic of 159  
0.79. Among the CEV groups, the highest rate ratio for severe disease was solid organ 160  
transplant recipients: with no risk conditions as reference category, the unadjusted rate 161  
ratio associated with receipt of a solid organ transplant among the double-vaccinated was 162  
101 (95% CI 47 to 214) for severe disease and 29.9 (95% CI 21.0 to 42.7) for hospitalisation. 163

## Shielding cohort 164

By the date of the latest extract of the shielding list in July 2021, 8230 (4%) of the 202510 165  
individuals who had ever been on the shielding list had been diagnosed with COVID-19, 166  
and 18893 (9%) had been removed from the list for other reasons. Fig 1 shows the fitted 167  
incidence per month of any diagnosis and of severe cases in Poisson regression models fitted 168  
to the entire cohort. The incidence of any diagnosed COVID-19 in the shielding cohort fell 169  
from 1 December to a nadir in late April. Despite the incidence of any diagnosed COVID-19 170  
rising steeply from 1 May onwards, the incidence of severe COVID-19 rose only slightly. 171

Table S6 shows the incidence of severe COVID-19 in double-vaccinated CEV individuals, 172  
by subgroup. In the highest risk group – solid organ transplant recipients – the incidence 173  
was 1.5 per 1000 per month (35 cases in 23678 person-months of follow-up). Of the 35 174  
severe cases among double-vaccinated solid organ transplants, only one had received a 175  
transplant less than one year before presentation date. 176

## Discussion 177

### Statement of principal findings 178

1. Although the efficacy of two doses of vaccine against severe COVID-19 in those 179  
without risk conditions remains around 90%, it is now clear that efficacy in clinically 180  
extremely vulnerable individuals is somewhat lower at 73%. On the scale of absolute 181  
risk reduction, a reduction by three-quarters of fivefold elevated risk in unvaccinated 182  
CEV individuals is of course greater than a reduction of baseline risk by nine-tenths. 183

2. Among double-vaccinated individuals, those who have designated risk conditions or are CEV account for 85% of severe cases and 75% of hospitalised cases. 184  
185

3. In comparison with double-vaccinated individuals of the same age and sex without risk conditions, double-vaccinated CEV individuals remain at relatively high risk of severe COVID-19. For double-vaccinated solid organ transplant recipients the rate of severe disease is 100-fold higher, though the absolute risk is about 1 in 1000 per month. 186  
187  
188  
189

## Strengths and limitations 190

Strengths of this study are the elimination of calendar time effects by the matched case-control design, the comprehensive linkage to e-health records and the focus on severe cases as main outcome measure. Hospitalised cases may include some test-positive individuals whose admission or continued stay in hospital was for another underlying diagnosis: this in turn may lead to underestimation of vaccine efficacy against COVID-19, especially in risk groups with comorbidities. Such misclassification is less likely to occur with the narrow definition of severe COVID-19 used in the REACT-SCOT study. 191  
192  
193  
194  
195  
196  
197

Even in this large cohort, the numbers of severe cases in some CEV subgroups are too small for vaccine efficacy against severe disease to be estimated accurately within these subgroups. Another limitation is that as most immunosuppressants and drugs for cancer are prescribed only in hospital where prescribing records are not held in electronic form, we cannot study the relation of risk to different classes of immunosuppressant drugs. 198  
199  
200  
201  
202

## Relation to other studies 203

Two studies in England have examined vaccine efficacy in the CEV. One estimated that efficacy of the Pfizer vaccine against hospitalisation waned more rapidly in the CEV than in those who were not CEV [10]. The other study estimated efficacy of two doses of any vaccine against symptomatic COVID-19 as 87% (based on combining the age-stratified estimates) in those who had been advised to shield [11]. However without regular scheduled testing, estimation of vaccine efficacy against infection (rather than hospitalisation) is subject to ascertainment bias, and this problem is not entirely overcome by restricting to symptomatic cases or by test-negative case-control designs. 204  
205  
206  
207  
208  
209  
210  
211

## Policy implications. 212

Our results show that the risk of severe COVID-19 after two doses of vaccine is highest in solid organ transplant recipients, and that this elevated risk is not restricted to the first six months after transplant as the UK Joint Committee on Vaccination and Immunisation apparently assumed in its original recommendation that “a third primary dose be offered to individuals aged 12 years and over with severe immunosuppression” [12]. Subsequent recommendations have broadened the criteria for third primary doses and booster doses. For solid organ transplant recipients, passive immunization therapies may be an option now that they have been licensed in the UK for prevention in “those who have a medical condition making them unlikely to respond to or be protected by vaccination” [13]. 213  
214  
215  
216  
217  
218  
219  
220  
221

## **Declarations** 222

### **Public and Patient Involvement statement:** 223

This study was conducted under approvals from the Public Benefit and Privacy Panel for Health and Social Care which includes public and patient representatives. 224  
225

### **Ethics approval** 226

This study was performed within Public Health Scotland as part of its statutory duty to monitor and investigate public health problems. Under the UK Policy Framework for Health and Social Care Research set out by the NHS Health Research Authority, this does not fall within the definition of research and ethical review was therefore not required. Individual consent is not required for Public Health Scotland staff to process personal data to perform specific tasks in the public interest that fall within its statutory role. The statutory basis for this is set out in Public Health Scotland's privacy notice. 227  
228  
229  
230  
231  
232  
233

### **Transparency declaration** 234

PM as the manuscript's guarantor affirms: that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned and registered have been explained. This manuscript has been generated directly from the source data by a reproducible research pipeline. 235  
236  
237  
238  
239

### **Funding** 240

No specific funding was received for this study. 241

### **Data Availability** 242

The component datasets used here are available via the Public Benefits and Privacy Panel for Health and Social Care at <https://www.informationgovernance.scot.nhs.uk/pbpphsc/> for researchers who meet the criteria for access to confidential data. All source code used for derivation of variables, statistical analysis and generation of this manuscript is available on [https://github.com/pmckeigue/covid-scotland\\_public](https://github.com/pmckeigue/covid-scotland_public). 243  
244  
245  
246  
247

### **Competing interest** 248

All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. 249  
250

### **Acknowledgements** 251


We thank Jen Bishop, Ciara Gribben, Bob Taylor and David Caldwell for undertaking the linkage analysis within Public Health Scotland, 252  
253



## References

1. McKeigue PM, Weir A, Bishop J, McGurnaghan SJ, Kennedy S, McAllister D, et al. Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. *PLOS Medicine*. 2020;17: e1003374. doi:10.1371/journal.pmed.1003374
2. McKeigue PM, Kennedy S, Weir A, Bishop J, McGurnaghan SJ, McAllister D, et al. Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: The REACT-SCOT case-control study. *BMC medicine*. 2021;19: 51. doi:10.1186/s12916-021-01907-8
3. McKeigue PM, McAllister DA, Caldwell D, Gribben C, Bishop J, McGurnaghan S, et al. Relation of severe COVID-19 in Scotland to transmission-related factors and risk conditions eligible for shielding support: REACT-SCOT case-control study. *BMC medicine*. 2021;19: 149. doi:10.1186/s12916-021-02021-5
4. McKeigue PM, McAllister DA, Bishop J, Hutchinson S, Robertson C, Lone N, et al. Efficacy of COVID-19 vaccination in individuals designated as clinically extremely vulnerable in Scotland. *F1000Research*. 2021;10: 663. doi:10.12688/f1000research.53812.1
5. Health Protection Scotland. Search criteria for highest risk patients for shielding. [https://hpspubsrepo.blob.core.windows.net/hps-website/nss/3008/documents/1\\_covid-19-search-criteria-highest-risk-patients.pdf](https://hpspubsrepo.blob.core.windows.net/hps-website/nss/3008/documents/1_covid-19-search-criteria-highest-risk-patients.pdf): Public Health Scotland; 2020 May.
6. Rodrigues LC, Smith PG. Use of the case-control approach in vaccine evaluation: Efficacy and adverse effects. *Epidemiologic Reviews*. 1999;21: 56–72. doi:10.1093/oxfordjournals.epirev.a017988
7. Breslow NE, Day NE, Halvorsen KT, Prentice RL, Sabai C. Estimation of multiple relative risk functions in matched case-control studies. *American Journal of Epidemiology*. 1978;108: 299–307. doi:10.1093/oxfordjournals.aje.a112623
8. Greenland S, Thomas DC. On the need for the rare disease assumption in case-control studies. *American Journal of Epidemiology*. 1982;116: 547–553. doi:10.1093/oxfordjournals.aje.a113439
9. McKeigue PM, McAllister DA, Hutchinson SJ, Robertson C, Stockton D, Colhoun HM, et al. Efficacy of vaccination against severe COVID-19 in relation to Delta variant and time since second dose: The REACT-SCOT case-control study. Cold Spring Harbor Laboratory Press; 2021. p. 2021.09.12.21263448. doi:10.1101/2021.09.12.21263448
10. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. *Public Health England*; 2021 Sep. doi:10.1101/2021.09.15.21263583
11. Whitaker HJ, Tsang RS, Byford R, Andrews NJ, Sherlock J, Pillai S, et al. Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups. <https://khub.net/documents/135939561/430986542/RCGP+VE+riskgroups+paper.pdf/a6b54cd9-419d-9b63-e2bf-5dc796f5a91f>; 2021.
12. Joint Committee on Vaccination and Immunisation. Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary dose vaccination.

<a href="https://www.gov.uk/government/publications/third-primary-covid-19-vaccine-dose-for-people-who-are-immunosuppressed-jcvi-advice/joint-committee-on-vaccination-and-immunisation-jcvi-advice-on-third-primary-dose-vaccination">https://www.gov.uk/government/publications/third-primary-covid-19-vaccine-dose-for-people-who-are-immunosuppressed-jcvi-advice/joint-committee-on-vaccination-and-immunisation-jcvi-advice-on-third-primary-dose-vaccination</a> : Joint Committee on Vaccination and Immunisation; 2021 Sep.	299 300 301 302
13. Medicines & Healthcare products Regulatory Agency. Summary of Product Characteristics for Ronapreve. GOV.UK.	303 304
<a href="https://www.gov.uk/government/publications/regulatory-approval-of-ronapreve/summary-of-product-characteristics-for-ronapreve">https://www.gov.uk/government/publications/regulatory-approval-of-ronapreve/summary-of-product-characteristics-for-ronapreve</a> ; 2021.	305 306 307



**Fig 1.** Fitted values for monthly incidence of any case and severe case in the shielding cohort, based on Poisson regression with spline terms for calendar time

**Table 1.** Numbers of cases of severe COVID-19 and matched controls, by risk group and vaccine product

	Controls (50086)	Cases (5644)
Care home	2471 (5%)	951 (17%)
SIMD quintile (integer)	3 (1 to 4)	2 (1 to 3)
Number of adults in household	2 (1 to 2)	2 (1 to 2)
Number of drug classes	4 (1 to 8)	8 (4 to 12)
Recent hospital stay	1062 (2%)	1479 (26%)
<b>Risk group</b>		
No risk condition	28661 (57%)	1576 (28%)
Moderate risk condition	17603 (35%)	2891 (51%)
Solid organ transplant	54 (0%)	70 (1%)
Specific cancers	522 (1%)	160 (3%)
Severe respiratory	1821 (4%)	504 (9%)
Rare diseases	179 (0%)	56 (1%)
On immunosuppressants	388 (1%)	104 (2%)
Additional conditions	858 (2%)	283 (5%)
<b>Vaccination status</b>		
Not vaccinated	36874 (74%)	4494 (80%)
1 dose mRNA vaccine	2277 (5%)	247 (4%)
1 dose AZ vaccine	2693 (5%)	260 (5%)
2 doses mRNA vaccine	2630 (5%)	142 (3%)
2 doses AZ vaccine	5595 (11%)	499 (9%)

Presentation dates from 1 December 2020 to 8 September 2021.

Median and interquartile range given for numeric variables

Severe COVID-19 defined as entry to critical care or death within 28 days of presentation.

Controls matched for age, sex, and primary care practice on date of presentation of case.

Vaccination status is number of doses administered at least 14 days before presentation date

**Table 2.** Rate ratios for severe COVID-19 within risk groups associated with vaccine dose: unvaccinated as reference category

Effect	1 dose vaccine		2 doses vaccine	
	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value
No risk condition	0.30 (0.24, 0.38)	$5 \times 10^{-26}$	0.06 (0.04, 0.07)	$2 \times 10^{-102}$
Moderate risk condition	0.42 (0.35, 0.50)	$8 \times 10^{-20}$	0.11 (0.09, 0.14)	$1 \times 10^{-82}$
Eligible for shielding	0.53 (0.39, 0.72)	$7 \times 10^{-5}$	0.27 (0.21, 0.36)	$1 \times 10^{-22}$

Presentation dates from 1 December 2020 to 8 September 2021.

Severe COVID-19 defined as entry to critical care or death within 28 days of presentation.

Controls matched for age, sex, and primary care practice on date of presentation of case.

Adjusted for care home residence, number of adults in household, number of drug classes and recent hospital stay as covariates

Rate ratios estimated in multivariable conditional logistic regression with all variables in model

Vaccination status is doses administered at least 14 days before presentation date

**Table 3.** Rate ratios for severe COVID-19 associated with vaccine dose within clinically extremely vulnerable subgroups/2, 1

Effect	1 dose vaccine		2 doses vaccine	
	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value
Solid organ transplant	0.93 (0.22, 3.85)	0.9	0.60 (0.24, 1.51)	0.3
Specific cancers	0.51 (0.22, 1.17)	0.1	0.34 (0.20, 0.59)	$1 \times 10^{-4}$
Severe respiratory	0.65 (0.42, 1.01)	0.06	0.18 (0.13, 0.26)	$9 \times 10^{-21}$
Rare diseases	0.81 (0.26, 2.57)	0.7	0.10 (0.03, 0.28)	$2 \times 10^{-5}$
On immunosuppressants	0.47 (0.20, 1.12)	0.09	0.53 (0.29, 0.97)	0.04
Additional conditions	0.24 (0.12, 0.49)	$9 \times 10^{-5}$	0.24 (0.15, 0.39)	$2 \times 10^{-9}$

Presentation dates from 1 December 2020 to 8 September 2021.

Severe COVID-19 defined as entry to critical care or death within 28 days of presentation.

Controls matched for age, sex, and primary care practice on date of presentation of case.

Adjusted for care home residence, number of adults in household, number of drug classes and recent hospital stay as covariates

Rate ratios estimated in multivariable conditional logistic regression with all variables in model

Vaccination status is number of doses administered at least 14 days before presentation date

**Table 4.** Rate ratios for severe COVID-19 within risk groups: vaccine dose and product encoded as categoric variable with unvaccinated as reference category

Effect	1 dose vaccine		2 doses vaccine	
	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value
No risk condition: mRNA vaccine	0.25 (0.18, 0.34)	$7 \times 10^{-18}$	0.04 (0.03, 0.06)	$9 \times 10^{-46}$
No risk condition: AZ vaccine	0.35 (0.26, 0.47)	$3 \times 10^{-12}$	0.07 (0.05, 0.09)	$7 \times 10^{-73}$
Moderate risk condition: mRNA vaccine	0.52 (0.42, 0.65)	$2 \times 10^{-8}$	0.07 (0.05, 0.09)	$7 \times 10^{-55}$
Moderate risk condition: AZ vaccine	0.30 (0.23, 0.40)	$9 \times 10^{-17}$	0.13 (0.10, 0.17)	$2 \times 10^{-60}$
Eligible for shielding: mRNA vaccine	0.48 (0.28, 0.82)	0.007	0.27 (0.17, 0.41)	$3 \times 10^{-9}$
Eligible for shielding: AZ vaccine	0.52 (0.36, 0.75)	$5 \times 10^{-4}$	0.28 (0.21, 0.37)	$3 \times 10^{-19}$

Presentation dates from 1 December 2020 to 8 September 2021.

Adjusted for care home residence, number of adults in household, number of drug classes dispensed, recent hospital stay and risk category.

Controls matched for age, sex, and primary care practice on date of presentation of case.

Vaccination status is number of doses administered at least 14 days before presentation date

**Table 5.** Risk factors for severe COVID-19 in those who had received 2 doses of vaccine at least 14 days before

	Controls (8225)	Cases (641)	Univariate		Multivariable	
			Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value
Care home	207 (3%)	57 (9%)	3.11 (2.14, 4.52)	$2 \times 10^{-9}$	1.70 (1.10, 2.63)	0.02
SIMD quintile (integer)	3 (1 to 4)	2 (1 to 4)	0.79 (0.74, 0.85)	$4 \times 10^{-10}$	0.92 (0.84, 1.00)	0.06
Number of adults in household	2 (1 to 2)	2 (1 to 2)	0.95 (0.88, 1.03)	0.3	1.01 (0.92, 1.10)	0.9
Number of hospital diagnoses	0 (0 to 3)	5 (1 to 8)	1.28 (1.25, 1.31)	$8 \times 10^{-75}$	1.06 (1.02, 1.09)	0.001
Number of non-cardiovascular drug classes	2 (1 to 5)	7 (4 to 10)	1.27 (1.24, 1.30)	$7 \times 10^{-92}$	1.13 (1.10, 1.17)	$6 \times 10^{-18}$
Recent hospital stay	151 (2%)	90 (14%)	7.5 (5.5, 10.2)	$1 \times 10^{-36}$	3.83 (2.68, 5.47)	$2 \times 10^{-13}$
<b>Risk group</b>						
No risk condition	4940 (60%)	95 (15%)		.		.
Moderate risk condition	2673 (32%)	303 (47%)	5.4 (4.2, 7.0)	$1 \times 10^{-37}$	2.93 (2.20, 3.89)	$1 \times 10^{-13}$
Solid organ transplant	15 (0%)	35 (5%)	101 (47, 214)	$7 \times 10^{-33}$	31.4 (13.8, 71.2)	$2 \times 10^{-16}$
Specific cancers	77 (1%)	36 (6%)	26.0 (15.8, 43.0)	$3 \times 10^{-37}$	12.7 (7.3, 22.0)	$2 \times 10^{-19}$
Severe respiratory	289 (4%)	82 (13%)	13.2 (9.3, 18.7)	$2 \times 10^{-47}$	4.75 (3.17, 7.11)	$4 \times 10^{-14}$
Rare diseases	32 (0%)	6 (1%)	8.2 (3.2, 21.1)	$1 \times 10^{-5}$	3.24 (1.21, 8.66)	0.02
On immunosuppressants	61 (1%)	31 (5%)	26.2 (15.1, 45.3)	$2 \times 10^{-31}$	13.3 (7.3, 24.3)	$3 \times 10^{-17}$
Additional conditions	138 (2%)	53 (8%)	15.5 (10.2, 23.6)	$6 \times 10^{-38}$	6.3 (3.9, 10.0)	$3 \times 10^{-14}$

Severe COVID-19 is defined by entry to critical care or fatal outcome

Percentages are column percentages for each variable

Rate ratios are from conditional logistic regression models matched for age, sex and general practice

Univariate rate ratios are for models with a single covariate

Multivariable rate ratios are for a model including all covariates shown in the table

## Supplementary Material

308

**Table S1.** Numbers of cases of hospitalized or fatal COVID-19 and matched controls, by risk group and vaccine product

	Controls (202071)	Cases (21671)
Care home	5790 (3%)	2053 (9%)
SIMD quintile (integer)	3 (1 to 4)	2 (1 to 3)
Number of adults in household	2 (1 to 2)	2 (1 to 2)
Number of drug classes	3 (0 to 6)	6 (2 to 10)
Recent hospital stay	3304 (2%)	5333 (25%)
<b>Risk group</b>		
No risk condition	133911 (66%)	8802 (41%)
Moderate risk condition	55806 (28%)	9214 (43%)
Solid organ transplant	255 (0%)	192 (1%)
Specific cancers	1600 (1%)	506 (2%)
Severe respiratory	5630 (3%)	1538 (7%)
Rare diseases	575 (0%)	157 (1%)
On immunosuppressants	1462 (1%)	330 (2%)
Additional conditions	2832 (1%)	932 (4%)
<b>Vaccination status</b>		
Not vaccinated	128417 (64%)	15369 (71%)
1 dose mRNA vaccine	11812 (6%)	788 (4%)
1 dose AZ vaccine	12562 (6%)	1440 (7%)
2 doses mRNA vaccine	16983 (8%)	774 (4%)
2 doses AZ vaccine	32213 (16%)	3294 (15%)

Presentation dates from 1 December 2020 to 8 September 2021.

Median and interquartile range given for numeric variables

Controls matched for age, sex, and primary care practice on date of presentation of case.

Vaccination status is number of doses administered at least 14 days before presentation date

**Table S2.** Rate ratios for hospitalised or fatal COVID-19 within risk groups associated with vaccine dose: unvaccinated as reference category

Effect	1 dose vaccine		2 doses vaccine	
	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value
No risk condition	0.36 (0.33, 0.39)	$2 \times 10^{-118}$	0.14 (0.12, 0.15)	$2 \times 10^{-408}$
Moderate risk condition	0.41 (0.37, 0.45)	$2 \times 10^{-70}$	0.17 (0.15, 0.18)	$10 \times 10^{-304}$
Eligible for shielding	0.58 (0.50, 0.69)	$5 \times 10^{-11}$	0.32 (0.29, 0.37)	$1 \times 10^{-75}$

Presentation dates from 1 December 2020 to 8 September 2021.

Controls matched for age, sex, and primary care practice on date of presentation of case.

Adjusted for care home residence, number of adults in household, number of drug classes and recent hospital stay as covariates

Rate ratios estimated in multivariable conditional logistic regression with all variables in model

Vaccination status is doses administered at least 14 days before presentation date

**Table S3.** Rate ratios for hospitalised or fatal COVID-19 associated with vaccine dose within clinically extremely vulnerable subgroups, with unvaccinated as reference category

Effect	1 dose vaccine		2 doses vaccine	
	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value
Solid organ transplant	0.70 (0.33, 1.46)	0.3	0.60 (0.38, 0.95)	0.03
Specific cancers	0.88 (0.59, 1.32)	0.5	0.31 (0.23, 0.41)	$2 \times 10^{-16}$
Severe respiratory	0.55 (0.43, 0.70)	$9 \times 10^{-7}$	0.28 (0.24, 0.33)	$3 \times 10^{-50}$
Rare diseases	0.48 (0.25, 0.92)	0.03	0.31 (0.19, 0.50)	$1 \times 10^{-6}$
On immunosuppressants	0.74 (0.47, 1.15)	0.2	0.40 (0.29, 0.54)	$2 \times 10^{-9}$
Additional conditions	0.46 (0.33, 0.63)	$2 \times 10^{-6}$	0.32 (0.26, 0.39)	$7 \times 10^{-26}$

Presentation dates from 1 December 2020 to 8 September 2021.

Severe COVID-19 defined as entry to critical care or death within 28 days of presentation.

Controls matched for age, sex, and primary care practice on date of presentation of case.

Adjusted for care home residence, number of adults in household, number of drug classes and recent hospital stay as covariates

Rate ratios estimated in multivariable conditional logistic regression with all variables in model

Vaccination status is number of doses administered at least 14 days before presentation date

**Table S4.** Rate ratios for hospitalized or fatal COVID-19 within risk groups associated with vaccine dose by product within risk groups, with unvaccinated as reference category

Effect	1 dose vaccine		2 doses vaccine	
	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value
No risk condition: mRNA vaccine	0.26 (0.23, 0.29)	$4 \times 10^{-101}$	0.08 (0.07, 0.09)	$4 \times 10^{-235}$
No risk condition: AZ vaccine	0.52 (0.46, 0.58)	$1 \times 10^{-29}$	0.19 (0.17, 0.20)	$9 \times 10^{-236}$
Moderate risk condition: mRNA vaccine	0.36 (0.31, 0.41)	$3 \times 10^{-47}$	0.09 (0.08, 0.11)	$5 \times 10^{-220}$
Moderate risk condition: AZ vaccine	0.48 (0.42, 0.54)	$6 \times 10^{-31}$	0.22 (0.20, 0.25)	$3 \times 10^{-186}$
Eligible for shielding: mRNA vaccine	0.41 (0.30, 0.55)	$2 \times 10^{-9}$	0.23 (0.19, 0.29)	$3 \times 10^{-41}$
Eligible for shielding: AZ vaccine	0.71 (0.59, 0.86)	$3 \times 10^{-4}$	0.38 (0.33, 0.43)	$7 \times 10^{-51}$

Presentation dates from 1 December 2020 to 8 September 2021.

Adjusted for care home residence, number of adults in household, number of drug classes dispensed, recent hospital stay and risk category.

Controls matched for age, sex, and primary care practice on date of presentation of case.

Vaccination status is number of doses administered at least 14 days before presentation date



**Table S5.** Risk factors for hospitalised or fatal COVID-19 in those who had received 2 doses of vaccine at least 14 days before

	Controls (8225)	Cases (641)	Univariate		Multivariable	
			Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value
Care home	1127 (2%)	213 (5%)	1.90 (1.59, 2.26)	$7 \times 10^{-13}$	0.81 (0.66, 1.00)	0.05
SIMD quintile (integer)	3 (1 to 4)	2 (1 to 4)	0.81 (0.78, 0.83)	$2 \times 10^{-49}$	0.88 (0.86, 0.91)	$5 \times 10^{-13}$
Number of adults in household	2 (1 to 2)	2 (1 to 2)	1.02 (0.99, 1.05)	0.3	1.05 (1.02, 1.09)	0.002
Number of hospital diagnoses	0 (0 to 3)	4 (1 to 7)	1.28 (1.27, 1.29)	$2 \times 10^{-448}$	1.09 (1.08, 1.11)	$5 \times 10^{-37}$
Number of non-cardiovascular drug classes	2 (1 to 5)	6 (3 to 9)	1.23 (1.21, 1.24)	$4 \times 10^{-446}$	1.11 (1.10, 1.12)	$2 \times 10^{-74}$
Recent hospital stay	925 (2%)	830 (20%)	11.6 (10.4, 13.1)	$9 \times 10^{-385}$	6.6 (5.8, 7.5)	$5 \times 10^{-185}$
<b>Risk group</b>						
No risk condition	30516 (62%)	999 (25%)	.	.	.	.
Moderate risk condition	15102 (31%)	1925 (47%)	3.62 (3.32, 3.95)	$1 \times 10^{-184}$	1.80 (1.63, 1.99)	$2 \times 10^{-30}$
Solid organ transplant	97 (0%)	94 (2%)	29.9 (21.0, 42.7)	$2 \times 10^{-78}$	9.2 (6.2, 13.7)	$1 \times 10^{-27}$
Specific cancers	449 (1%)	154 (4%)	9.8 (8.0, 12.2)	$5 \times 10^{-100}$	3.86 (3.04, 4.90)	$1 \times 10^{-28}$
Severe respiratory	1599 (3%)	454 (11%)	8.3 (7.2, 9.5)	$3 \times 10^{-209}$	2.87 (2.45, 3.37)	$1 \times 10^{-38}$
Rare diseases	162 (0%)	46 (1%)	8.2 (5.7, 11.8)	$1 \times 10^{-30}$	3.46 (2.33, 5.15)	$8 \times 10^{-10}$
On immunosuppressants	461 (1%)	117 (3%)	8.3 (6.6, 10.5)	$1 \times 10^{-68}$	3.74 (2.87, 4.86)	$9 \times 10^{-23}$
Additional conditions	810 (2%)	279 (7%)	10.1 (8.6, 12.0)	$2 \times 10^{-163}$	3.67 (3.02, 4.46)	$6 \times 10^{-39}$

Percentages are column percentages for each variable

Rate ratios are from conditional logistic regression models matched for age, sex and general practice

Univariate rate ratios are for models with a single covariate

Multivariable rate ratios are for a model including all covariates shown in the table

**Table S6.** Incidence of severe COVID-19 in clinically extremely vulnerable individuals who had received 2 doses of vaccine at least 14 days before, by risk subgroup

Risk group	Number of severe cases	Person-months	Rate / 1000
Solid organ transplant	35	23678	1.48
Specific cancers	33	93896	0.35
Additional / rare conditions	59	210801	0.28
Severe respiratory	80	303250	0.26
On immunosuppressants	30	118649	0.25